Zebrafish as an Orthotopic Tumor Model for Retinoblastoma Mimicking Routes of Human Metastasis.
RB355
WERI-RB-1
Y79
childhood eye cancer
malignant retinal tumor
orthotopic transplantation
retinoblastoma
zebrafish
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 Nov 2022
25 Nov 2022
Historique:
received:
04
10
2022
revised:
16
11
2022
accepted:
21
11
2022
entrez:
11
12
2022
pubmed:
12
12
2022
medline:
12
12
2022
Statut:
epublish
Résumé
Retinoblastoma (RB) is the most common eye cancer in children that has a high mortality rate when left untreated. Mouse models for retinoblastoma have been established but are time- and cost-intensive. The aim of this work was to evaluate an orthotopic transplantation model of retinoblastoma in zebrafish that also allows for tracking migratory routes and to explore advantages and disadvantages with respect to drug testing. Three fluorescence-labeled retinoblastoma cell lines (RB355, WERI-RB-1, Y79) were injected into the left eye of two-day-old zebrafish, while the un-injected right eye served as control. The migratory trajectories of injected retinoblastoma cells were observed until 8 days post injection (dpi), both in lateral and dorsal view, and measuring fluorescence intensity of injected cells was done for RB355 cells. Time until the onset of migration and routes for all three retinoblastoma cell lines were comparable and resulted in migration into the brain and ventricles of the forebrain, midbrain and hindbrain. Involvement of the optic nerve was observed in 10% of injections with the RB355 cell line, 15% with Y79 cells and 5% with WERI-RB-1 cells. Fluorescence intensity of injected RB355 cells showed an initial increase until five dpi, but then decreased with high variability until the end of observation. The zebrafish eye is well suited for the analysis of migratory routes in retinoblastoma and closely mirrors patterns of retinoblastoma metastases in humans.
Sections du résumé
BACKGROUND
BACKGROUND
Retinoblastoma (RB) is the most common eye cancer in children that has a high mortality rate when left untreated. Mouse models for retinoblastoma have been established but are time- and cost-intensive. The aim of this work was to evaluate an orthotopic transplantation model of retinoblastoma in zebrafish that also allows for tracking migratory routes and to explore advantages and disadvantages with respect to drug testing.
METHODS
METHODS
Three fluorescence-labeled retinoblastoma cell lines (RB355, WERI-RB-1, Y79) were injected into the left eye of two-day-old zebrafish, while the un-injected right eye served as control. The migratory trajectories of injected retinoblastoma cells were observed until 8 days post injection (dpi), both in lateral and dorsal view, and measuring fluorescence intensity of injected cells was done for RB355 cells.
RESULTS
RESULTS
Time until the onset of migration and routes for all three retinoblastoma cell lines were comparable and resulted in migration into the brain and ventricles of the forebrain, midbrain and hindbrain. Involvement of the optic nerve was observed in 10% of injections with the RB355 cell line, 15% with Y79 cells and 5% with WERI-RB-1 cells. Fluorescence intensity of injected RB355 cells showed an initial increase until five dpi, but then decreased with high variability until the end of observation.
CONCLUSION
CONCLUSIONS
The zebrafish eye is well suited for the analysis of migratory routes in retinoblastoma and closely mirrors patterns of retinoblastoma metastases in humans.
Identifiants
pubmed: 36497295
pii: cancers14235814
doi: 10.3390/cancers14235814
pmc: PMC9736091
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Kinderaugenkrebsstiftung (KAKS, German Children Eye Cancer Foundation)
ID : 2017-UKE04f
Références
Sci Rep. 2017 Mar 16;7:44601
pubmed: 28300160
Ophthalmic Paediatr Genet. 1991 Mar;12(1):49-56
pubmed: 1679230
Dev Neurobiol. 2012 Mar;72(3):302-27
pubmed: 21595048
Cell Cycle. 2004 Jul;3(7):952-9
pubmed: 15190215
Hum Genet. 1985;70(4):291-301
pubmed: 4018796
Int J Cancer. 1990 Jul 15;46(1):125-32
pubmed: 2365495
Cell Cycle. 2004 Jul;3(7):917-9
pubmed: 15254429
Development. 2005 May;132(9):2057-67
pubmed: 15788456
Neuron. 2019 Jul 3;103(1):21-38.e5
pubmed: 31147152
Sci Rep. 2015 Jul 14;5:10351
pubmed: 26169357
Nat Rev Dis Primers. 2015 Aug 27;1:15021
pubmed: 27189421
Cancers (Basel). 2022 Feb 28;14(5):
pubmed: 35267571
Exp Cell Res. 2019 Feb 15;375(2):92-99
pubmed: 30584916
J Vis Exp. 2009 Apr 06;(26):
pubmed: 19352312
Lancet Oncol. 2013 Apr;14(4):327-34
pubmed: 23498719
Nat Rev Mol Cell Biol. 2013 May;14(5):297-306
pubmed: 23594950
Lancet. 2012 Apr 14;379(9824):1436-46
pubmed: 22414599
Acta Neuropathol Commun. 2019 Aug 26;7(1):137
pubmed: 31451106
Mol Cancer. 2013 Jul 09;12:71
pubmed: 23835085
Pediatr Blood Cancer. 2010 Jul 15;55(1):60-6
pubmed: 20486172
Prog Mol Biol Transl Sci. 2011;100:287-330
pubmed: 21377629
Oncogene. 2019 Mar;38(12):2056-2075
pubmed: 30401983
Int J Ophthalmol. 2020 Feb 18;13(2):325-341
pubmed: 32090044
Histochem Cell Biol. 2015 Mar;143(3):325-38
pubmed: 25326674
Asia Pac J Ophthalmol (Phila). 2016 Jul-Aug;5(4):260-4
pubmed: 27488068
Lancet Glob Health. 2022 Mar;10(3):e380-e389
pubmed: 35093202